Search for: "Grant v. Janssen Research " Results 1 - 20 of 34
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Jan 2022, 4:46 pm by INFORRM
Julian Assange has been granted permission to appeal to the UK Supreme Court against the December 2021 decision to extradite him to the US. [read post]
6 Dec 2021, 6:24 am by Lisa Larrimore Ouellette
Phase 2/3 clinical trials began in February 2021 for Pfizer/BioNTech and Janssen and included pregnant people. [read post]
22 Oct 2021, 11:36 am by Pamela Wolf
They argued that Johnson & Johnson/Janssen used cells ultimately derived from an aborted fetus to produce its vaccine, as did Moderna and Pfizer/BioNTech in researching their vaccines. [read post]
22 Oct 2021, 11:36 am by Pamela Wolf
They argued that Johnson & Johnson/Janssen used cells ultimately derived from an aborted fetus to produce its vaccine, as did Moderna and Pfizer/BioNTech in researching their vaccines. [read post]
21 Feb 2021, 4:07 pm by INFORRM
  Mr Justice Tony O’Connor granted an ex-parte application by Mr Ganley’s lawyers permitting legal papers to be served outside the jurisdiction on CNN. [read post]
28 Apr 2019, 7:45 am
In 1977 Edmund Kitch said that the grant of a patent could also have the purpose of encouraging further research on the patented subject matter, giving an analogy to a mining claim of staking out an area for further research. [read post]
4 May 2017, 1:00 am by Jiao Yuxin
Relevant Judicial Practice Boehringer Ingelheim Pharma GmbH & Co KG v. [read post]
18 Nov 2016, 12:44 am by John Collins
The judge held that the “undue burden” concept in English law (particularly as outlined by Arnold J in Eli Lilly v Janssen in 2014) was not particularly helpful under Australian law. [read post]
29 Aug 2016, 1:19 pm by Michael Grossman
Risperdal is the name Janssen patented and used when marketing the product. [read post]
9 Nov 2015, 7:39 am
Merck Sharp & Dohme v Ono Pharmaceutical [2015] EWHC 2973 (Pat), decided on 22 October by Mr Justice Birss in the Patents Court, England and Wales, is a decidedly unbifurcated ruling, being a full-blooded infringement-and-invalidity action running to 243 paragraphs. [read post]
24 Apr 2013, 8:31 am by Rebecca Tushnet
Food & Drug Law Institute Annual Conference Top 20 Cases in Food & Drug Law in 2012 and Cases to Watch in 2013 Bill Janssen, Charleston School of Law: Weddle v. [read post]
2 Nov 2011, 2:00 am by Marie Louise
Research & Diagnostic Systems (Pharma Patents) US: Roundup Ready® Soybeans: Patent exhaustion in self-replicating biotechnologies (IP Osgoode) US: FDA continues efforts to expand power over intrastate commerce (FDA Law Blog) US: Defendants’ persistence in pursuing “baseless inequitable conduct claim” justified award of attorneys’ fees to plaintiff: Pfizer et. al v. [read post]
11 Jan 2011, 11:07 pm by Kelly
Supreme Court to take on patent settlement agreements: Louisiana Wholesale Drug Co et al v Bayer et al (FDA Law Blog) US: BIO joins 170 business, research institutions and organisations to urge caution in Microsoft v i4i case (PatentlyBIOtech) US: Galderma wins important victory in fight against Leo’s psoriasis patent covering vitamin D, corticosteroid composition for ‘dermal use’ (Reexamination Alert) US: Déjà vu! [read post]
15 Dec 2010, 2:17 am by Kelly
Becton, Dickinson & Co (Intellectual Property Law Blog) US: Regents of the University of California pursue new patent re-examination in District Court (Patents Post Grant Blog) US: Microsoft v i4i, the burden of proof and the pharma sector (PatLit) US: IRS issues notice to implement annual fee on brand drugs (FDA Law Blog) US: Bright ‘orphan’ ideas blossom (FDA Law Blog) US: Amicus briefs in AMP v USPTO (Patent Docs) (Patent Docs) (Patent Docs) US:… [read post]
10 Feb 2010, 4:47 pm
(Patent Docs) Pataday (Olopatadine hydrochloride ophthalmic solution) – US: Patent infringement complaint filed in S D Indiana following a Paragraph IV certification: Alcon Research, Ltd. et al. v. [read post]